Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Current Urology Reports
|
April 18, 2009
Does chemotherapy have a role before hormone-resistant disease develops?
James P Dean, Celestia S Higano
European Journal of Haematology
|
November 1, 2022
Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study
Xiaomeng Yue, David Hallett, Yangyang Liu, et al.
Cancer Research
|
January 21, 2006
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms
Claes Bavik, Ilsa Coleman, James P Dean, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 25, 2019
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, et al.
Clinical Pharmacology in Drug Development
|
May 29, 2026
Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data
Sarah A Buckley, Suliman Al-Fayoumi, James P Dean, et al.
Leukemia Research
|
February 21, 2021
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia
Isabelle G Solman, Lisa K Blum, Jan A Burger, et al.
British Journal of Haematology
|
December 5, 2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
John N Allan, Tait Shanafelt, Adrian Wiestner, et al.
Future Oncology (London, England)
|
April 21, 2016
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
David Belada, Pencho Georgiev, Shaker Dakhil, et al.
Blood Advances
|
June 14, 2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Carol Moreno, Isabelle G Solman, Constantine S Tam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E Ahn, Xin Tian, David Ipe, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Current Urology Reports
|
April 18, 2009
Does chemotherapy have a role before hormone-resistant disease develops?
James P Dean, Celestia S Higano
European Journal of Haematology
|
November 1, 2022
Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study
Xiaomeng Yue, David Hallett, Yangyang Liu, et al.
Cancer Research
|
January 21, 2006
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms
Claes Bavik, Ilsa Coleman, James P Dean, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 25, 2019
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, et al.
Clinical Pharmacology in Drug Development
|
May 29, 2026
Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data
Sarah A Buckley, Suliman Al-Fayoumi, James P Dean, et al.
Leukemia Research
|
February 21, 2021
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia
Isabelle G Solman, Lisa K Blum, Jan A Burger, et al.
British Journal of Haematology
|
December 5, 2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
John N Allan, Tait Shanafelt, Adrian Wiestner, et al.
Future Oncology (London, England)
|
April 21, 2016
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
David Belada, Pencho Georgiev, Shaker Dakhil, et al.
Blood Advances
|
June 14, 2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Carol Moreno, Isabelle G Solman, Constantine S Tam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E Ahn, Xin Tian, David Ipe, et al.
Page
of 3